Lv11
70 积分 2024-07-04 加入
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial
4个月前
已完结
Claudin 18.2 as a novel therapeutic target
4个月前
已完结
Claudin 18.2 as a novel therapeutic target
6个月前
已完结
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
9个月前
已完结
RECIST 1.1—Update and clarification: From the RECIST committee
9个月前
已完结
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
9个月前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
9个月前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
9个月前
已完结
皖公网安备34019202002308
